Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Prokidney (PROK) over the last 4 years, with Sep 2025 value amounting to $5.2 million.

  • Prokidney's Capital Expenditures rose 116.18% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year increase of 527.30%. This contributed to the annual value of $29.5 million for FY2024, which is 13.71% down from last year.
  • Prokidney's Capital Expenditures amounted to $5.2 million in Q3 2025, which was up 67.00% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Prokidney's Capital Expenditures ranged from a high of $27.9 million in Q3 2023 and a low of $306,000 during Q4 2022.
  • Its 3-year average for Capital Expenditures is $6.7 million, with a median of $2.4 million in 2024.
  • As far as peak fluctuations go, Prokidney's Capital Expenditures soared by 8,769.52% in 2023, and later tumbled by 91.40% in 2024.
  • Over the past 4 years, Prokidney's Capital Expenditures (Quarterly) stood at $306,000 in 2022, then skyrocketed by 413.73% to $1.6 million in 2023, then spiked by 1,522.71% to $25.5 million in 2024, then spiked by 116.18% to $5.2 million in 2025.
  • Its Capital Expenditures stands at $5.2 million for Q3 2025, versus $3.1 million for Q2 2025 and $1.1 million for Q1 2025.